Xenon Pharmaceuticals Return on Tangible Equity 2012-2022 | XENE
Current and historical return on tangible equity values for Xenon Pharmaceuticals (XENE) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Xenon Pharmaceuticals Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2022-03-31 |
$-0.08B |
$0.54B |
-20.28% |
| 2021-12-31 |
$-0.08B |
$0.55B |
-23.12% |
| 2021-09-30 |
$-0.06B |
$0.25B |
-26.86% |
| 2021-06-30 |
$-0.06B |
$0.26B |
-26.19% |
| 2021-03-31 |
$-0.04B |
$0.28B |
-17.60% |
| 2020-12-31 |
$-0.03B |
$0.17B |
-15.34% |
| 2020-09-30 |
$-0.03B |
$0.18B |
-16.59% |
| 2020-06-30 |
$-0.03B |
$0.19B |
-19.85% |
| 2020-03-31 |
$-0.04B |
$0.19B |
-33.79% |
| 2019-12-31 |
$-0.04B |
$0.09B |
-47.95% |
| 2019-09-30 |
$-0.04B |
$0.08B |
-44.19% |
| 2019-06-30 |
$-0.04B |
$0.08B |
-44.22% |
| 2019-03-31 |
$-0.04B |
$0.09B |
-43.70% |
| 2018-12-31 |
$-0.03B |
$0.10B |
-43.69% |
| 2018-09-30 |
$-0.03B |
$0.11B |
-54.87% |
| 2018-06-30 |
$-0.03B |
$0.05B |
-65.82% |
| 2018-03-31 |
$-0.03B |
$0.03B |
-68.79% |
| 2017-12-31 |
$-0.03B |
$0.04B |
-66.67% |
| 2017-09-30 |
$-0.03B |
$0.04B |
-54.21% |
| 2017-06-30 |
$-0.03B |
$0.05B |
-48.33% |
| 2017-03-31 |
$-0.03B |
$0.06B |
-46.09% |
| 2016-12-31 |
$-0.02B |
$0.06B |
-37.70% |
| 2016-09-30 |
$-0.02B |
$0.07B |
-34.85% |
| 2016-06-30 |
$-0.02B |
$0.05B |
-28.81% |
| 2016-03-31 |
$-0.01B |
$0.06B |
-16.19% |
| 2015-12-31 |
$-0.02B |
$0.06B |
-25.40% |
| 2015-09-30 |
$-0.00B |
$0.06B |
-4.55% |
| 2015-06-30 |
$0.01B |
$0.06B |
8.51% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$1.548B |
$0.018B |
|
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.
|
